| 沙利度胺联合放疗治疗食管癌长期生存分析 |
| |
| 引用本文： | 张华,于静萍,倪新初,王坚,金建华,朱麒,邓玲慧,孙志强,孙苏平.沙利度胺联合放疗治疗食管癌长期生存分析[J].中华放射医学与防护杂志,2015,35(6):437-440. |
| |
| 作者姓名： | 张华 于静萍 倪新初 王坚 金建华 朱麒 邓玲慧 孙志强 孙苏平 |
| |
| 作者单位： | 213003 常州, 南京医科大学附属常州第二人民医院放疗科;213003 常州, 南京医科大学附属常州第二人民医院放疗科;213003 常州, 南京医科大学附属常州第二人民医院放疗科;213003 常州, 南京医科大学附属常州第二人民医院放疗科;213003 常州, 南京医科大学附属常州第二人民医院放疗科;213003 常州, 南京医科大学附属常州第二人民医院放疗科;213003 常州, 南京医科大学附属常州第二人民医院放疗科;213003 常州, 南京医科大学附属常州第二人民医院放疗科;213003 常州, 南京医科大学附属常州第二人民医院放疗科 |
| |
| 基金项目： | 江苏省卫生厅指导性科研项目(Z201220);常州市卫生局重大项目(ZD201105);常州市科技支撑社会发展项目(CE20125021) |
| |
| 摘 要： | 目的 研究沙利度胺下调食管癌患者放疗中血清血管内皮生长因子(vascular endothelial growth factor,VEGF)水平对食管癌患者长期生存的影响。方法 根据81例食管癌患者放疗中血清VEGF水平分为用药组(沙利度胺)32例和未用药组49例,通过随访观察分析其总生存率(OS)和无进展生存率(PFS),根据32例使用沙利度胺处理后的血清VEGF水平变化,又分降低组20例和升高组12例,分析其OS和PFS。对预后因素进行单因素和多因素分析。结果 用药组和未用药组的中位生存期及1、3年生存率分别为17.0个月、59.4%、31.5%和18.7个月、56.4%、28.6%;两组的OS和PFS分别比较,差异均无统计学意义。VEGF水平降低组和升高组的中位生存期及1、3年生存率分别为19.7个月、65.0%、42.1%和10.7个月、43.3%、8.3%;两组OS和PFS比较,差异均有统计学意义(χ2=4.345、4.157,P<0.05)。多因素分析显示,临床分期是食管癌患者总生存率的独立预后因素,性别、病变部位对患者预后没有影响。结论 对于用药后VEGF水平降低患者,沙利度胺联合放疗能够增加食管癌患者远期疗效。
|
| 关 键 词： | 食管癌 放疗 血管内皮生长因子 沙利度胺 |
| 收稿时间： | 2015/2/26 0:00:00 |
Long-term survival analysis of thalidomide combined with radiotherapy for patients with esophageal carcinoma |
| |
| Zhang Hu,Yu Jingping,Ni Xinchu,Wang Jian,Jin Jianhu,Zhu Qi,Deng Linghui,Sun Zhiqiang and Sun Suping.Long-term survival analysis of thalidomide combined with radiotherapy for patients with esophageal carcinoma[J].Chinese Journal of Radiological Medicine and Protection,2015,35(6):437-440. |
| |
| Authors: | Zhang Hu Yu Jingping Ni Xinchu Wang Jian Jin Jianhu Zhu Qi Deng Linghui Sun Zhiqiang and Sun Suping |
| |
| Institution: | Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China;Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China;Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China;Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China;Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China;Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China;Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China;Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China;Department of Radiotherapy, the Changzhou Second People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou 213003, China |
| |
| Abstract: | |
| |
| Keywords: | Esophageal cancer Radiotherapy Vascular endothelial growth factor Thalidomide |
|
| 点击此处可从《中华放射医学与防护杂志》浏览原始摘要信息 |
| 点击此处可从《中华放射医学与防护杂志》下载免费的PDF全文 |
|
